MARKETS
Earnings

Starling Oncology Q2 EPS $(0.08) Up From $(0.15) YoY, Sales $161.282M Up From $119.802M YoY

Aug 7, 2026 · 01:48 PM ET· updated 1h ago

Starling Oncology (NASDAQ:STLN) reported quarterly losses of $(0.08) per share. This is a 46.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported $161.282 million in

Share
Why It Matters

Starling Oncology lost less money per share than it did a year ago, and its sales grew a lot—going from about $120M to $161M. When a company loses less money while making more sales, it's moving in a better direction, so watch if this trend keeps going.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.